Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| SAB Biotherapeutics Inc | SABS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.888 | 07:00:14 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.888 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.3657 - 1.45 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.888 | USD |
SAB Biotherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 46.56M | 52.32M | - | 23.9M | -18.74M | -0.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
SAB Biotherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SABS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.96 | 0.97 | 0.85 | 0.9107884 | 131,619 | -0.072 | -7.5% |
| 1 Month | 0.96 | 0.9721 | 0.63 | 0.906843 | 72,425 | -0.072 | -7.5% |
| 3 Months | 0.60 | 1.05 | 0.41 | 0.8362641 | 65,311 | 0.288 | 48.0% |
| 6 Months | 0.9202 | 1.05 | 0.41 | 0.8238407 | 58,473 | -0.0322 | -3.5% |
| 1 Year | 1.00 | 1.45 | 0.3657 | 0.9106832 | 383,752 | -0.112 | -11.2% |
| 3 Years | 7.80 | 12.09 | 0.3657 | 2.62 | 272,378 | -6.91 | -88.62% |
| 5 Years | 7.80 | 12.09 | 0.3657 | 2.62 | 272,378 | -6.91 | -88.62% |
SAB Biotherapeutics Description
| SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression. |
